News

While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.

Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.

The latest trading day saw Abbott (ABT) settling at $110.47, representing a +1.41% change from its previous close.

The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.

While Medtronic has outperformed relative to the Dow over the past three months, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Medtronic (MDT) lifted its full-year outlook on Tuesday as the medical-device maker reported better-

The benefit of whole milk-based baby formula is that it more closely mirrors the fat blend found in breast milk than powdered baby formula.

Despite Abbott Laboratories' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.

Abbott Laboratories (NYSE:ABT) launched Similac 360 Total Care Made With Whole Milk, a commercially sterile ready-to-feed liquid infant formula made with whole milk in the U.S. The product is the first of its kind in the U.S. market to combine whole milk with a ready-to-feed liquid format. The formula uses whole milk and a blend of human milk oligosaccharides to more closely mirror key elements of breast milk. The launch expands Abbott's infant nutrition portfolio and targets parents seeking...

Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.

Abbott Laboratories is leaning into the Make America Healthy Movement, launching a new infant formula made with whole milk.

GE HealthCare (GEHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

With Amulet 360, Abbott aims to capture share from Boston Scientific in the market for devices that seal the heart’s left atrial appendage to lower stroke risk.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the...

Abbott (ABT) concluded the recent trading session at $111.59, signifying a -2.2% move from its prior day's close.

Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.

U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.

Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program before the end of the year.

Abbott Laboratories (NYSE:ABT) received FDA De Novo authorization for its Libre Duo 10 Day, described as the first dual glucose ketone monitoring wearable for U.S. patients. The Libre Duo 10 Day is cleared for use in people with diabetes as young as age 2 and is intended to support real time tracking of both glucose and ketone levels. Abbott plans integration of Libre Duo 10 Day with leading insulin pump systems in the U.S. over the coming years as part of its broader diagnostics and digital...

Pfizer Inc. (NYSE:PFE) and Abbott Laboratories (NYSE:ABT) offer investors two very different dividend stories. Pfizer (NYSE:PFE) is working to rebuild growth before major patent expirations arrive, while Abbott (NYSE:ABT) is combining a long dividend-growth record with a more diversified healthcare portfolio. Pfizer (NYSE:PFE) may offer turnaround potential, but Abbott’s (NYSE:ABT) latest results present the steadier […]

On Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.

For long-suffering owners of Boston Scientific, here’s how to get paid a meaningful cash income now, yours to keep no matter what, in exchange for capping your gains at a higher price.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the U.S. to monitor ketone levels continuously. It also represents the first global system to track blood sugar and ketones simultaneously within a single unit. Clinical Data And De Novo Pathway The agency granted marketing authorization

Aug 26 (Reuters) - Boston Scientific said on Wednesday that a cybersecurity incident had disrupted global operations, including some information systems used to process and ship customer orders.

His AbbVie purchase was a big move into a high-yielding dividend stock.

Its growth profile stands well above major sector peers.

Three catalysts, one reshuffling, and a Fed that refuses to move

Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth.

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.